

# David Baldwin

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10997180/publications.pdf>

Version: 2024-02-01

23  
papers

2,109  
citations

567281

15  
h-index

839539

18  
g-index

23  
all docs

23  
docs citations

23  
times ranked

2641  
citing authors

#	ARTICLE	IF	CITATIONS
1	Biological markers for anxiety disorders, OCD and PTSD: A consensus statement. Part II: Neurochemistry, neurophysiology and neurocognition. World Journal of Biological Psychiatry, 2017, 18, 162-214.	2.6	226
2	Biological markers for anxiety disorders, OCD and PTSD – a consensus statement. Part I: Neuroimaging and genetics. World Journal of Biological Psychiatry, 2016, 17, 321-365.	2.6	118
3	Safety and Tolerability of Antidepressants. , 2016, , 149-166.		1
4	Lithium and sexual dysfunction: an under-researched area. Human Psychopharmacology, 2015, 30, 66-69.	1.5	33
5	The relationships among separation anxiety disorder, adult attachment style and agoraphobia in patients with panic disorder. Journal of Anxiety Disorders, 2014, 28, 741-746.	3.2	29
6	Neurotic, stress-related and somatoform disorders. , 2010, , 453-491.		2
7	Resolution of sexual dysfunction during acute treatment of major depression with milnacipran. Human Psychopharmacology, 2008, 23, 527-532.	1.5	29
8	Suicide by veterinary surgeons. Veterinary Record, 2008, 162, 355-356.	0.3	0
9	Selective serotonin re-uptake inhibitor treatment-emergent sexual dysfunction: randomized double-blind placebo-controlled parallel-group fixed-dose study of a potential adjuvant compound, VML-670. Journal of Psychopharmacology, 2008, 22, 55-63.	4.0	15
10	Mental health and wellbeing survey. Veterinary Record, 2007, 161, 360-360.	0.3	2
11	Generalised anxiety disorder. Lancet, The, 2006, 368, 2156-2166.	13.7	265
12	Resolution of sexual dysfunction during double-blind treatment of major depression with reboxetine or paroxetine. Journal of Psychopharmacology, 2006, 20, 91-96.	4.0	60
13	Clinical evaluation of psychotropic drugs. Psychiatry (Abingdon, England), 2004, 3, 14-17.	0.2	1
14	Anxiety disorders: does one treatment fit all?. International Journal of Psychiatry in Clinical Practice, 2004, 8, 31-35.	2.4	0
15	Placebo-controlled studies in depression: necessary, ethical and feasible. European Archives of Psychiatry and Clinical Neuroscience, 2003, 253, 22-28.	3.2	59
16	Sexual side-effects of antidepressant and antipsychotic drugs. Advances in Psychiatric Treatment, 2003, 9, 202-210.	0.5	129
17	The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Bipolar Disorders, Part II: Treatment of Mania. World Journal of Biological Psychiatry, 2003, 4, 5-13.	2.6	148
18	The future of antidepressant pharmacotherapy. World Psychiatry, 2003, 2, 3-8.	10.4	28

#	ARTICLE	IF	CITATIONS
19	World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Bipolar Disorders, Part I: Treatment of Bipolar Depression. World Journal of Biological Psychiatry, 2002, 3, 115-124.	2.6	161
20	The economic consequences of social phobia. Journal of Affective Disorders, 2002, 68, 221-233.	4.1	123
21	Social Functioning in Depression. Journal of Clinical Psychiatry, 2000, 61, 268-275.	2.2	464
22	Paroxetine in social phobia/social anxiety disorder. British Journal of Psychiatry, 1999, 175, 120-126.	2.8	216
23	Treatment of generalised anxiety and somatoform disorders. , 0, , 525-541.		0